Cargando…
Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that involves multiple organs and disproportionality affects females, especially African Americans from 15 to 44 years of age. SLE can lead to end organ damage including kidneys, lungs, cardiovascular and neuropsychiatric systems, wi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546393/ https://www.ncbi.nlm.nih.gov/pubmed/33101319 http://dx.doi.org/10.3389/fimmu.2020.586737 |
_version_ | 1783592221642063872 |
---|---|
author | Harden, Olivia C. Hammad, Samar M. |
author_facet | Harden, Olivia C. Hammad, Samar M. |
author_sort | Harden, Olivia C. |
collection | PubMed |
description | Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that involves multiple organs and disproportionality affects females, especially African Americans from 15 to 44 years of age. SLE can lead to end organ damage including kidneys, lungs, cardiovascular and neuropsychiatric systems, with cardiovascular complications being the primary cause of death. Usually, SLE is diagnosed and its activity is assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Systemic Lupus International Collaborating Clinics Damage Index (SLICC/ACR), and British Isles Lupus Assessment Group (BILAG) Scales, which unfortunately often occurs after a certain degree of systemic involvements, disease activity or organ damage already exists. There is certainly a need for the identification of early biomarkers to diagnose and assess disease activity as well as to evaluate disease prognosis and response to treatment earlier in the course of the disease. Here we review advancements made in the area of sphingolipidomics as a diagnostic/prognostic tool for SLE and its co-morbidities. We also discuss recent reports on differential sphingolipid metabolism and blood sphingolipid profiles in SLE-prone animal models as well as in diverse cohorts of SLE patients. In addition, we address targeting sphingolipids and their metabolism as a method of treating SLE and some of its complications. Although such treatments have already shown promise in preventing organ-specific pathology caused by SLE, further investigational studies and clinical trials are warranted. |
format | Online Article Text |
id | pubmed-7546393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75463932020-10-22 Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus Harden, Olivia C. Hammad, Samar M. Front Immunol Immunology Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that involves multiple organs and disproportionality affects females, especially African Americans from 15 to 44 years of age. SLE can lead to end organ damage including kidneys, lungs, cardiovascular and neuropsychiatric systems, with cardiovascular complications being the primary cause of death. Usually, SLE is diagnosed and its activity is assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Systemic Lupus International Collaborating Clinics Damage Index (SLICC/ACR), and British Isles Lupus Assessment Group (BILAG) Scales, which unfortunately often occurs after a certain degree of systemic involvements, disease activity or organ damage already exists. There is certainly a need for the identification of early biomarkers to diagnose and assess disease activity as well as to evaluate disease prognosis and response to treatment earlier in the course of the disease. Here we review advancements made in the area of sphingolipidomics as a diagnostic/prognostic tool for SLE and its co-morbidities. We also discuss recent reports on differential sphingolipid metabolism and blood sphingolipid profiles in SLE-prone animal models as well as in diverse cohorts of SLE patients. In addition, we address targeting sphingolipids and their metabolism as a method of treating SLE and some of its complications. Although such treatments have already shown promise in preventing organ-specific pathology caused by SLE, further investigational studies and clinical trials are warranted. Frontiers Media S.A. 2020-09-25 /pmc/articles/PMC7546393/ /pubmed/33101319 http://dx.doi.org/10.3389/fimmu.2020.586737 Text en Copyright © 2020 Harden and Hammad. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Harden, Olivia C. Hammad, Samar M. Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus |
title | Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus |
title_full | Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus |
title_fullStr | Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus |
title_full_unstemmed | Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus |
title_short | Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus |
title_sort | sphingolipids and diagnosis, prognosis, and organ damage in systemic lupus erythematosus |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546393/ https://www.ncbi.nlm.nih.gov/pubmed/33101319 http://dx.doi.org/10.3389/fimmu.2020.586737 |
work_keys_str_mv | AT hardenoliviac sphingolipidsanddiagnosisprognosisandorgandamageinsystemiclupuserythematosus AT hammadsamarm sphingolipidsanddiagnosisprognosisandorgandamageinsystemiclupuserythematosus |